Genmab — August 2022
-
-
-
-
-
bibob..Tusinde tak for gode links.
-
Fra links: "At a median follow-up of 56.2 months, patients treated with the humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months derived a significant overall survival (OS) benefit compared with those who received the regimen for less than 18 months (HR, 0.16; 95% CI, 0.1-0.25; P < .0001). Notably, the median OS was not reached in the group with the longer treatment duration vs 20.5 months among patients....
-
who were treated for less than 18 months"
-
Biotech Stocks Facing FDA Decision In September https://www.proinvestor.com/investornyt/871985/biotech-stocks-facing-fda-decision-in-september
-
Trancript fra Q&A med CEO Adam Stensberg/Zealand Pharma Q2 afholdt i går kl. 15. https://www.proinvestor.com/ir/q-and-a/dk
-
Godmorgen.
-
Godmorgen.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind